{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:36:17Z","timestamp":1768718177095,"version":"3.49.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2002,1,22]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Background<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            Patients with prior CABG with a subsequent non\u2013ST-segment elevation acute coronary syndrome (ACS) pose an increasingly important clinical problem. Although GP IIb\/IIIa inhibitors have improved the outcome of patients with ACS, their efficacy in patients with prior CABG has not been previously evaluated.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Methods and Results<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            We analyzed the 30- and 180-day outcomes of patients with prior CABG enrolled in the Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. In this trial, which evaluated the efficacy of eptifibatide in patients with ACS, 1134 patients (12%) with prior CABG and 8321 without prior CABG were enrolled. After adjusting for differences in baseline characteristics and treatment, patients with prior CABG had a significantly higher mortality rates at 30 days (hazard ratio [HR], 1.45 [95% CI, 1.06 to 1.98];\n            <jats:italic>P<\/jats:italic>\n            =0.019) and at 180 days (HR, 1.32 [95% CI, 1.04 to 1.67];\n            <jats:italic>P<\/jats:italic>\n            =0.021). At 30 days, there was a similar effect on the primary end point of death or myocardial infarction in the eptifibatide group versus the placebo group in prior CABG patients (unadjusted HR, 0.90 [95% CI, 0.67 to 1.20]) and in patients without a history of CABG (unadjusted HR, 0.89 [95% CI, 0.80 to 0.99]).\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Conclusions<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            Patients with prior CABG with non\u2013ST-segment elevation ACS have a significantly worse prognosis than do patients without a history of CABG. The treatment effect of eptifibatide in the prior CABG group was similar to the effect seen in patients without prior CABG.\n          <\/jats:p>","DOI":"10.1161\/hc0302.102578","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T23:16:07Z","timestamp":1027898167000},"page":"322-327","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":52,"title":["Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting"],"prefix":"10.1161","volume":"105","author":[{"given":"Marino","family":"Labinaz","sequence":"first","affiliation":[{"name":"From the University of Ottawa Heart Institute (M.L.), Ottawa, Ontario, Canada; Duke Clinical Research Institute (R.K., K.P., R.A.H., R.M.C.), Durham, NC; Mid America Heart Institute (S.P.M.), Saint Luke\u2019s Hospital, Kansas City, Mo; COR Therapeutics (M.M.K.), South San Francisco, Calif; University Hospital (M.L.S.), Rotterdam, the Netherlands; Cleveland Clinic (E.J.T.), Cleveland, Ohio; and University of Alberta (P.W.A.), Edmonton, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakhi","family":"Kilaru","sequence":"additional","affiliation":[{"name":"From the University of Ottawa Heart Institute (M.L.), Ottawa, Ontario, Canada; Duke Clinical Research Institute (R.K., K.P., R.A.H., R.M.C.), Durham, NC; Mid America Heart Institute (S.P.M.), Saint Luke\u2019s Hospital, Kansas City, Mo; COR Therapeutics (M.M.K.), South San Francisco, Calif; University Hospital (M.L.S.), Rotterdam, the Netherlands; Cleveland Clinic (E.J.T.), Cleveland, Ohio; and University of Alberta (P.W.A.), Edmonton, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Pieper","sequence":"additional","affiliation":[{"name":"From the University of Ottawa Heart Institute (M.L.), Ottawa, Ontario, Canada; Duke Clinical Research Institute (R.K., K.P., R.A.H., R.M.C.), Durham, NC; Mid America Heart Institute (S.P.M.), Saint Luke\u2019s Hospital, Kansas City, Mo; COR Therapeutics (M.M.K.), South San Francisco, Calif; University Hospital (M.L.S.), Rotterdam, the Netherlands; Cleveland Clinic (E.J.T.), Cleveland, Ohio; and University of Alberta (P.W.A.), Edmonton, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Marso","sequence":"additional","affiliation":[{"name":"From the University of Ottawa Heart Institute (M.L.), Ottawa, Ontario, Canada; Duke Clinical Research Institute (R.K., K.P., R.A.H., R.M.C.), Durham, NC; Mid America Heart Institute (S.P.M.), Saint Luke\u2019s Hospital, Kansas City, Mo; COR Therapeutics (M.M.K.), South San Francisco, Calif; University Hospital (M.L.S.), Rotterdam, the Netherlands; Cleveland Clinic (E.J.T.), Cleveland, Ohio; and University of Alberta (P.W.A.), Edmonton, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"Kitt","sequence":"additional","affiliation":[{"name":"From the University of Ottawa Heart Institute (M.L.), Ottawa, Ontario, Canada; Duke Clinical Research Institute (R.K., K.P., R.A.H., R.M.C.), Durham, NC; Mid America Heart Institute (S.P.M.), Saint Luke\u2019s Hospital, Kansas City, Mo; COR Therapeutics (M.M.K.), South San Francisco, Calif; University Hospital (M.L.S.), Rotterdam, the Netherlands; Cleveland Clinic (E.J.T.), Cleveland, Ohio; and University of Alberta (P.W.A.), Edmonton, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten L.","family":"Simoons","sequence":"additional","affiliation":[{"name":"From the University of Ottawa Heart Institute (M.L.), Ottawa, Ontario, Canada; Duke Clinical Research Institute (R.K., K.P., R.A.H., R.M.C.), Durham, NC; Mid America Heart Institute (S.P.M.), Saint Luke\u2019s Hospital, Kansas City, Mo; COR Therapeutics (M.M.K.), South San Francisco, Calif; University Hospital (M.L.S.), Rotterdam, the Netherlands; Cleveland Clinic (E.J.T.), Cleveland, Ohio; and University of Alberta (P.W.A.), Edmonton, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Califf","sequence":"additional","affiliation":[{"name":"From the University of Ottawa Heart Institute (M.L.), Ottawa, Ontario, Canada; Duke Clinical Research Institute (R.K., K.P., R.A.H., R.M.C.), Durham, NC; Mid America Heart Institute (S.P.M.), Saint Luke\u2019s Hospital, Kansas City, Mo; COR Therapeutics (M.M.K.), South San Francisco, Calif; University Hospital (M.L.S.), Rotterdam, the Netherlands; Cleveland Clinic (E.J.T.), Cleveland, Ohio; and University of Alberta (P.W.A.), Edmonton, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Topol","sequence":"additional","affiliation":[{"name":"From the University of Ottawa Heart Institute (M.L.), Ottawa, Ontario, Canada; Duke Clinical Research Institute (R.K., K.P., R.A.H., R.M.C.), Durham, NC; Mid America Heart Institute (S.P.M.), Saint Luke\u2019s Hospital, Kansas City, Mo; COR Therapeutics (M.M.K.), South San Francisco, Calif; University Hospital (M.L.S.), Rotterdam, the Netherlands; Cleveland Clinic (E.J.T.), Cleveland, Ohio; and University of Alberta (P.W.A.), Edmonton, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"From the University of Ottawa Heart Institute (M.L.), Ottawa, Ontario, Canada; Duke Clinical Research Institute (R.K., K.P., R.A.H., R.M.C.), Durham, NC; Mid America Heart Institute (S.P.M.), Saint Luke\u2019s Hospital, Kansas City, Mo; COR Therapeutics (M.M.K.), South San Francisco, Calif; University Hospital (M.L.S.), Rotterdam, the Netherlands; Cleveland Clinic (E.J.T.), Cleveland, Ohio; and University of Alberta (P.W.A.), Edmonton, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[{"name":"From the University of Ottawa Heart Institute (M.L.), Ottawa, Ontario, Canada; Duke Clinical Research Institute (R.K., K.P., R.A.H., R.M.C.), Durham, NC; Mid America Heart Institute (S.P.M.), Saint Luke\u2019s Hospital, Kansas City, Mo; COR Therapeutics (M.M.K.), South San Francisco, Calif; University Hospital (M.L.S.), Rotterdam, the Netherlands; Cleveland Clinic (E.J.T.), Cleveland, Ohio; and University of Alberta (P.W.A.), Edmonton, Alberta, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_3_1_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198506273122603"},{"key":"e_1_3_3_2_2","first-page":"1173","volume":"2","year":"1982","unstructured":"European Coronary Surgery Study Group. Long-term results of perspective randomized study of coronary artery bypass surgery in stable angina pectoris. Lancet. 1982; 2: 1173\u20131180.","journal-title":"Lancet"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198808113190603"},{"key":"e_1_3_3_4_2","first-page":"II-1","volume":"68","year":"1983","unstructured":"Campeau L, Enjalbert M, Lesperance J, et al. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation. 1983; 68 (suppl II): II-1\u2013II-7","journal-title":"Circulation"},{"key":"e_1_3_3_5_2","first-page":"59","volume":"53","year":"1984","unstructured":"Campeau L, Lesperance J, Bourassa M. Natural history of saphenous vein aortocoronary bypass grafts. Mod Concepts Cardiovasc Dis. 1984; 53: 59\u201363.","journal-title":"Mod Concepts Cardiovasc Dis"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(96)00206-9"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.97.9.916"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.112779"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.91.6.1659"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.101.19.2231"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)89383-6"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90016-0"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(88)90447-0"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.71.4.3871669"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207163270310"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(96)00344-0"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.97.24.2386"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382102"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390704"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382103"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.101.22.2557"},{"key":"e_1_3_3_22_2","first-page":"320","volume":"20","year":"1997","unstructured":"Chan AW, Ross J. Management of unstable coronary syndromes in patients with previous coronary artery bypass grafts following coronary angiography. Clin Invest Med. 1997; 20: 320\u2013326.","journal-title":"Clin Invest Med"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(96)00286-0"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00589-4"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00329-0"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(00)90014-0"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.103.3.363"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.102.24.2952"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.101.7.751"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10452-9"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00970-9"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00280-5"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371103"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.1.61"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00824-X"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/hc0302.102578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T01:40:11Z","timestamp":1715650811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/hc0302.102578"}},"subtitle":["Results From the Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial"],"short-title":[],"issued":{"date-parts":[[2002,1,22]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,1,22]]}},"alternative-id":["10.1161\/hc0302.102578"],"URL":"https:\/\/doi.org\/10.1161\/hc0302.102578","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1,22]]},"assertion":[{"value":"2002-01-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}